培唑帕尼致不良反应文献分析研究  

Literature analysis of adverse drug reactions induced by pazopanib

作　　者：张晓昕 吴明铭 阮贤妹[1] ZHANG Xiao-xin;WU Ming-ming;RUAN Xian-mei(Department of Pharmacy,Fuzhou First General Hospital Affiliated with Fujian Medical University,Fuzhou 350009,China;Department of Oncology,The First Afiliated Hospital of Fujian Medical University,Fuzhou 350005,China)

机构地区：[1]福建医科大学附属福州市第一总医院药学部,福州350009 [2]福建医科大学附属第一医院肿瘤内科,福州350005

出　　处：《中国新药杂志》2025年第5期553-560,共8页Chinese Journal of New Drugs

摘　　要：目的:分析培唑帕尼发生药物不良反应(adverse drug reactions,ADR)的临床特点与规律,为临床安全用药提供参考。方法:搜索PubMed、中国知网、万方和维普数据库,收集关于培唑帕尼所致ADR的文献报道并进行分析,检索时限为建库至2024年3月。结果:共纳入文献84篇,涉及89例病例,发生94例次ADR,其中新的ADR 21例。患者中男性55例(61.80%)、女性34例(38.20%),平均年龄(57.7±16.7)岁。培唑帕尼主要用于治疗肾透明细胞癌,占58.43%;其次是软组织肉瘤(soft tissue sarcoma,STS),占35.96%。多数ADR发生在用药后2个月内(55/94,58.51%);ADR累及器官/系统以皮肤及其附件为主(22.34%),其次为肝胆胰系统(13.83%)、呼吸系统(12.77%)和神经系统(12.77%),主要临床表现为可逆性后部脑病综合征(posterior reversible encephalopathy syndrome,PRES)和气胸。培唑帕尼致ADR自发性缓解的有5例(5.43%);需经药物治疗后好转的有74例(80.43%);经手术和(或)药物治疗后,严重延长病程或治疗后仍有后遗症的有8例(8.70%);死亡5例(5.43%)。结论:培唑帕尼所致ADR涉及不同性别与年龄段病人,累及多个系统/器官,不乏严重致死病例。临床使用应加强监测,及时识别ADR并对症处理,保障患者安全。Objective:To analyze the clinical characteristics and patterns of adverse drug reactions(ADR)of pazopanib,in order to provide a reference for the clinical safety of this drug.Methods:The databases of PubMed,CNKI,Wanfang and VIP were searched,and the literatures reporting adverse reactions caused by pazopanib were collected and analyzed.The studied period was from inception to March 2024.Results:A total of 84 literatures were included,involving 89 cases,reporting 94 ADR,among which 21 ADR were new.There were 55 male(61.80%)and 34 female(38.20%).Average age of patients was(57.7±16.7)years old.Pazopanib was mainly used for suprarenal epithelioma,accounting for 58.43%;followed by soft tissue sarcoma,accounting for 35.96%.Most of them occurred within 60 days after drug administration(55/94,58.51%).Organs/systems involved in ADR were mostly diseases of skin and subcutaneous tissue(accounting for 22.34%),followed by diseases of hepatobiliary pancreatic system(13.83%),respiratory system(12.77%)and nervous system(12.77%)which mainly manifested as posterior reversible encephalopathy syndrome and aerothorax.Five cases of pazopanib-induced ADR were recovered without doing anything(5.43%);74 cases were recovered after drug therapy(80.43%);8 cases had sequel after surgery,disease course and therapy prolonged(8.70%);and 5 death cases(5.43%).Conclusion:Pazopanib-induced ADR involve various organs/systems,and fatal cases.In the process of clinical medication,we should strengthen the observation and monitoring,as well as timely ADR disposal,to guarantee the safety of patients.

关 键 词：培唑帕尼 多靶点酪氨酸激酶抑制剂 药物不良反应 

分 类 号：R969.3[医药卫生—药理学]